JRP Bio signs three-party MOU with Kwangdong Pharmaceutical and Kyung Hee University MRC
Collaboration with Kwangdong's Natural Product Convergence R&D Division and the MRC for reinterpreting herbal medicine in cancer
JRP Bio (Jaein R&P Co., Ltd.) announced that it has signed a three-party memorandum of understanding on joint botanical development with Kwangdong Pharmaceutical's Natural Product Convergence R&D Division and Kyung Hee University's MRC.
JRP Bio makes it a working principle to research and validate with a network of universities, hospitals, Korean medicine clinics, pharmaceutical and food companies. The agreement is intended to carry research-stage botanical assets into products together with a pharmaceutical company.
JRP Bio previously signed a botanical drug commercialization MOU with Hanpoong Pharm (2022) and a joint R&D MOU with Sun Ten Pharmaceutical of Taiwan (2023).
About JRP Bio
JRP Bio (Jaein R&P Co., Ltd.) standardizes Korean medicine formulas and natural products, builds the evidence behind them, and secures approval to turn them into products people actually use. JRP stands for “Journey from Research to People.” The company received Korea's first IND for an oral botanical anticancer candidate, SH003, and holds 14 granted Korean patents and 42 SCI(E) publications.
Media contact
- Email bs@jrpbio.com
- Phone +82-2-6925-5568